European Commission approves Revolution Medicines' Rasonque as first broad RAS-targeted therapy for metastatic pancreatic cancer

The European Commission has authorised Revolution Medicines' Rasonque as an oral broad RAS-targeted treatment for previously treated metastatic pancreatic cancer, marking a significant advance in a disease with substantial unmet medical need.
Revolution Medicines announced on 16 November 2026 that the European Commission had approved Rasonque (daraxonrasib) as once-daily oral monotherapy for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic treatment, including patients with or without an identified RAS tumour mutation.
The authorisation establishes a new targeted treatment option for previously treated metastatic pancreatic cancer and represents a final European Commission regulatory decision rather than a CHMP recommendation, although practical availability across individual European countries will depend on subsequent pricing, reimbursement and market-access arrangements.
Field | Content |
Article Type | Approvals |
Company | Revolution Medicines |
Product Brand Name | Rasonque |
Active Ingredient | Daraxonrasib |
Drug Classification | Broad RAS-targeted therapy |
Drug Modality | Small-molecule targeted medicine |
Administration Route | Oral |
Dosing Frequency | Once daily |
Regulatory Authority | European Commission |
Announcement Date | 16 November 2026 |
Regulatory Decision | European Commission marketing authorisation |
Regulatory Status | Approved |
Geographic Scope | European Union |
Therapeutic Area | Oncology |
Cancer Type | Pancreatic adenocarcinoma |
Disease Stage | Metastatic |
Approved Treatment Setting | Following at least one prior systemic therapy |
Treatment Regimen | Daraxonrasib monotherapy |
Minimum Prior Treatment Requirement | At least one systemic therapy |
RAS Mutation Eligibility | Patients with or without an identified RAS tumour mutation |
Molecular Target | RAS signalling pathway |
First Broad RAS-Targeted Medicine Claim | Described as the first broad RAS-targeted medicine in metastatic pancreatic cancer |
Clinical Unmet Need | Limited treatment options in previously treated metastatic pancreatic cancer |
European Regulatory Milestone | Final marketing authorisation |
CHMP Recommendation Only | No |
Country-Level Reimbursement | Subject to national decisions |
Immediate Uniform EU Patient Access | Not established |
What Happened | The European Commission approved Rasonque for previously treated metastatic pancreatic adenocarcinoma. |
Why It Matters | The approval creates a new targeted therapeutic option in a cancer associated with major unmet clinical need. |
Clinical Significance | The authorised population includes patients irrespective of whether a RAS tumour mutation has been identified. |
Strategic Significance | Represents a major commercial and regulatory milestone for Revolution Medicines' RAS-targeted oncology programme. |
Access Significance | Marketing authorisation does not automatically establish reimbursement or availability in every EU member state. |
Key Takeaway | Rasonque has received European Commission approval as once-daily oral monotherapy for previously treated metastatic pancreatic cancer. |
What to Watch | National reimbursement decisions, European commercial rollout, treatment adoption and additional clinical evidence. |
Primary Source | Revolution Medicines |
Primary Source URL | https://revmed.gcs-web.com/news-releases/news-release-details/european-commission-approves-revolution-medicines-rasonquer |
Submitted Source | GlobeNewswire |
Submitted Source URL | https://www.globenewswire.com/news-release/2026/11/16/3404001/0/en/european-commission-approves-revolution-medicines-rasonque-daraxonrasib-the-first-broad-ras-targeted-medicine-in-metastatic-pancreatic-cancer.html |
Relevant Date | 16 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comments